Public opinion on access to mifepristone in the U.S. in 2023, by level of restriction
As of May 2023, 47 percent of U.S. adults were of the opinion that mifepristone should remain on the market and access should remain the same as it is now. While, 12 percent of U.S. adults thought that mifepristone should remain in the market with restricted access. More than half of all U.S. abortions are medical abortions performed by combining Mifepristone with misoprostol.